Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma

Conditions:   BRAF V600E Mutation Present;   Papillary Craniopharyngioma Interventions:   Drug: Vemurafenib;   Drug: Cobimetinib;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI) Not yet recruiting - verified July 2017
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials